Abstract
OS and PFS for the mITT population (A and C) and the PD-L1 CPS ≥ 20 subgroup (B and D). Data cutoff: April 27, 2021. The mITT population included all randomized patients who received the study intervention, whether or not randomized, but excluded those who were first dosed or randomized after the date of requesting immediate discontinuation of feladilimab and placebo. CI, confidence interval; HR, hazard ratio; mITT, modified intention-to-treat; OS, overall survival; PD-L1 CPS, programmed cell death ligand-1 combined positive score; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.